Surprisingly, RasGRP1 acts as a tumor suppressor in colonic epithelium; furthermore, RasGRP1 can be used as a biomarker for predicting the efficacy of anti-epidermal growth factor receptor (EGFR) therapy for CRC (colorectal cancer) patients [103,104]. Here, EGFR is linked to colorectal carcinoma.